Register
Login:
Share:
Email Facebook Twitter


HUM CEO updates on the Yanfolila Gold Project now fully funded.


Sareum Share Chat (SAR)



Share Price: 0.725Bid: 0.70Ask: 0.75Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 7.14%Open: 0.75High: 0.75Low: 0.725Yesterday’s Close: 0.725


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Thoth2
Posts: 1,159
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.725
Anthera pharmaceuticals
Today 00:10
I have already posted who I think is sniffing g tyk2.
I wish to add the above. Some similarities to prornai ( cash rich. Trading at less than cash. Recent failireb in LUPUS). Researched them yesterday and stupidly didn't follow my gut. Bouloved 62 % today.
Add to the mix. To achieve value we need several potential bidders. Tick many many boxes
 
horse1
Posts: 408
Off Topic
Opinion:No Opinion
Price:0.725
Total option gains for Tim, John
Today 00:07
Just done a quick calc on Tim and John's total share options if there was a total buy out. It always intrigues me why they are so precise on the number of options and the cost. Tim and John's options are exactly the same, as you would expect. For them to walk away with £5 million each, after paying the option price and CGT the buyout would be exactly £400 million. The new Guy would walk away with a cool £1 million. I am thinking like others on here, that news is close, maybe they had to get these options past by Xmas to ensure all the rewards are neat and tidy. GLA.
Borg
Posts: 157
Off Topic
Opinion:No Opinion
Price:0.00
RE: BBs dont really influence much
Wed 22:59
I think I would share their lack of appetite. To have as you say 200 to 700 million on the table as a potential buyout, or have anywhere from 5 to 10 years of hard slog achieving both results and failures as they go through the clinical stages, providing backup paperwork / supporting research and then arguing for those much needed milestone payments. The first option seems a much easier route to future happiness to me.

The guys are not getting any younger, could this be the reason for the directors loading up on shares now as they share this view to ??
potnak
Posts: 458
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.725
RE: BBs dont really influence much
Wed 22:41
For me, everything points to a buyout. I really don't think Tim and the board have the appetite to take this company to a billion pound valuation. It could easily be in 6 months. Just imagine positive early results from chk1, tyk2 being tweaked to be even more selective and Aurora fully overcoming the current challenges. A potential multi billion pound company could quite easily be bought for a fraction if that price. 10p for 260 million or 30p for less than 800 million.

Bigger prices have been paid for less potential.
Borg
Posts: 157
Off Topic
Opinion:Strong Buy
Price:0.725
Biotech Deals Nice Read
Wed 22:27
Although the crux of the article is about the trend for the huge sums agreed as part of the signed deal very rarely arriving, the flip side is that a number of the deals done on early stage drugs potentially can be bigger than normal.

https://www.statnews.com/2016/11/28/biotech-biobuck-deals/
Mr_Jay
Posts: 1,508
Off Topic
Opinion:No Opinion
Price:0.725
RE: BBs dont really influence much
Wed 22:19
I'm not suggesting that in the near future Darwin won't be bought out but for people to suggest within 6months approx without any foundation is simply ridiculous. Sorry but I can't buy that. Also it took 5yrs for chk1 to get a deal, not a great example if u want to get tyk2 deal is it?
Hardmed
Posts: 21
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.725
Thanks Hierarchy
Wed 22:18
Its things like that in a local magazine that confirms I'm invested in a well thought out company... It may not feel like it at times, especially after the share price dropping how it has of late after our licence deal, but its not a one trick pony and the guys at the top have a game plan...

"There are organisations which run networking events - they are like three days of speed-dating and we attend two or three a year. Companies like ProNAi turn up looking for companies like us, and I knew them from a previous incarnation"

(So they are being very proactive by the sounds of it.... )

"The plan is to increase the pipeline and reach, have three or four programmes in the clinic, and more staff, plus several licensing deals under our belt."

"It may be that one of those milestone payments will be worth much more than the value of the company, and then it would be a no-brainer for the licensee to acquire us"

Just my two pence worth....
thehierarchy
Posts: 233
Observation
Opinion:No Opinion
Price:0.725
Interview/Article
Wed 21:55
shoestring12
Posts: 126
Off Topic
Opinion:No Opinion
Price:0.725
RE: BBs dont really influence much
Wed 21:19
Hi Mr Jay, can't give you links, but when i read up on the net there is a lot of trials dropping like flies and failing. Or not great results as predicted. Tyk2 etc. is similar to these products and is still going strong. Results seem good or better than our competitors.
If they ( the big Pharma's) started their research again they would be lagging behind in the race. Plus they could use our compounds to mix with theirs to improve their results.
The cheapest way and quickest way forward for them would be to buy us out IMHO. and have sole benefit, and employ Tim and his team as consultants......in an ideal world.

I may be miles off but that's my opinion only, right or wrong...........however, i'm still p155ed off at the timing of their nice little wage rise.
Mr_Jay
Posts: 1,508
Off Topic
Opinion:No Opinion
Price:0.725
RE: BBs dont really influence much
Wed 21:06
Thoth2 right enough of the jokes n messing around. U seriously think a buyout? Based on what?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.